Delafloxacin: design, development and potential place in therapy
Drug Design, Development and Therapy, 2017 Francisco Javier Candel, Marina Peñuelas Department of Clinical Microbiology and Infectious Diseases, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Universidad Complutense, Madrid, Spain ...
Marina Peñuelas +1 more
exaly +8 more sources
The efficacy and adverse events of delafloxacin for treating acute bacterial skin and skin structure infections: A systematic review and meta-analysis [PDF]
Journal of Pharmacy and Bioallied Sciences, 2020 Background: Acute bacterial skin and skin structure infections (ABSSSI) cause significant morbidity and mortality in hospitalized patients and outpatients as well.
Syed Bilal Tanvir +4 more
doaj +4 more sources
Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis [PDF]
BMC Infectious Diseases, 2021 Background Delafloxacin is a novel fluoroquinolone with broad antibacterial activity against pathogens causing acute bacterial skin and skin structure infections (ABSSSI).
Ioanna Vlachaki +6 more
doaj +3 more sources
Spectroscopic Studies of Delafloxacin Meglumine
Chinese Journal of Magnetic Resonance, 2021 The structure of delafloxacin meglumine was analyzed by infrared absorption (IR), ultraviolet absorption (UV), nuclear magnetic resonance (1H NMR, 13C NMR, DEPT, 1H-1H COSY, 1H-13C HSQC and 1H-13C HMBC) spectroscopy, mass spectrometry and elemental ...
Xin-yi ZHAO +4 more
doaj +2 more sources
The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance [PDF]
Postępy Mikrobiologii, 2021 The growing problem of antimicrobial resistance has been classified by the World Health Organization (WHO) as one of the top ten threats to mankind. In a special report published in 2017, the WHO presented a list of microorganisms for which the search ...
Krajewska Joanna, Laudy Agnieszka Ewa
doaj +4 more sources
Updated Review on Clinically-Relevant Properties of Delafloxacin
Antibiotics, 2023 The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds.
Adrien Turban +3 more
doaj +3 more sources
Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel
Microbiology Spectrum, 2022 In vitro activities of delafloxacin and ciprofloxacin were evaluated against Burkholderia pseudomallei mutants expressing or lacking defined resistance-nodulation-cell division (RND) efflux pumps using CLSI methodology at pHs of 5.8 and 7.2. Delafloxacin
Sandra P. McCurdy +2 more
doaj +3 more sources
Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline [PDF]
Antibiotics, 2021 Novel antimicrobial agents, approved for clinical use in past years, represent potential treatment options for various infections. In this review, we summarize the most important medical and microbiological features of three recently approved ...
Béla Kocsis +2 more
doaj +3 more sources
Clinically Approved Antibiotics from 2010 to 2022 [PDF]
CHIMIA, 2023 This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. This time span saw the approval of four synthetic antibiotics (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives ...
Erik Jung, Karl Gademann
doaj +3 more sources
Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis [PDF]
Brazilian Journal of Infectious DiseasesThe aim of this study was to compare the in vitro activity of delafloxacin with other fluoroquinolones against bacterial pathogens recovered from inpatients with osteomyelitis, Acute Bacterial Skin and Skin-Structure Infections (ABSSSI).
Ághata Cardoso da Silva Ribeiro +10 more
doaj +2 more sources